{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:59:09Z","timestamp":1793278749642,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous condition characterized by diverse clinical phenotypes and underlying pathobiological mechanisms. Traditional \u201cone-size-fits-all\u201d management strategies have limited effectiveness in addressing this heterogeneity. The Treatable Traits (TTs) approach represents a precision medicine paradigm that targets specific, identifiable, and modifiable traits in individual patients, regardless of diagnostic labels. This paper explores the alignment between the TTs framework and emerging pharmacological therapies, with a particular focus on anti-inflammatory agents and bronchodilators currently under investigation. Each drug category is mapped to relevant TTs, such as eosinophilic or neutrophilic inflammation, corticosteroid resistance, chronic bronchitis, and frequent exacerbations. This review highlights the importance of biomarker-driven phenotyping and real-world data in designing TT-based clinical trials. It emphasizes challenges such as trait instability over time, comorbidity clustering, and trial design heterogeneity. Moreover, we advocate for incorporating digital health tools, long-term follow-up, and cost-effectiveness analyses to ensure translational relevance. In conclusion, integrating emerging therapies with the TTs approach holds substantial promise for personalizing COPD management, improving outcomes, and facilitating targeted drug development.<\/jats:p>","DOI":"10.1007\/s00408-025-00844-0","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:37:23Z","timestamp":1756903043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits"],"prefix":"10.1007","volume":"203","author":[{"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"844_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report. https:\/\/goldcopd.org\/2025-gold-report\/"},{"key":"844_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40248-016-0053-4","volume":"11","author":"M Barrecheguren","year":"2016","unstructured":"Barrecheguren M, Miravitlles M (2016) COPD heterogeneity: implications for management. Multidiscip Respir Med 11:14","journal-title":"Multidiscip Respir Med"},{"issue":"9979","key":"844_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","volume":"385","author":"PG Woodruff","year":"2015","unstructured":"Woodruff PG, Agust\u00ed A, Roche N, Singh D, Martinez FJ (2015) Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385(9979):1789\u20131798","journal-title":"Lancet"},{"issue":"4","key":"844_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40291-017-0266-z","volume":"21","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Rogliani P, Matera MG (2017) The challenges of precision medicine in COPD. Mol Diagn Ther 21(4):345\u2013355","journal-title":"Mol Diagn Ther"},{"key":"844_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106572","volume":"187","author":"A Agust\u00ed","year":"2021","unstructured":"Agust\u00ed A, Barnes N, Cruz AA, Gibson PG, Heaney LG, Inoue H, Leather D, Martinez FJ, McDonald VM, Oppenheimer J, Papi A, Pavord ID, Thomas M, Walker S (2021) Yates L (2021) Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respir Med 187:106572","journal-title":"Respir Med"},{"issue":"5","key":"844_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02058-2018","volume":"53","author":"VM McDonald","year":"2019","unstructured":"McDonald VM, Fingleton J, Agust\u00ed A, Hiles SA, Clark VL, Holland AE, Marks GB, Bardin PP, Beasley R, Pavord ID, Wark PAB, Gibson PG (2019) Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J 53(5):1802058","journal-title":"Eur Respir J"},{"issue":"2","key":"844_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agust\u00ed","year":"2016","unstructured":"Agust\u00ed A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID (2016) Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47(2):410\u2013419","journal-title":"Eur Respir J"},{"issue":"10356","key":"844_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","volume":"400","author":"D Stolz","year":"2022","unstructured":"Stolz D, Mkorombindo T, Schumann DM, Agust\u00ed A, Ash SY, Bafadhel M, Bai C, Chalmers JD, Criner GJ, Dharmage SC, Franssen FME, Frey U, Han M, Hansel NN, Hawkins NM, Kalhan R, Konigshoff M, Ko FW, Parekh TM, Powell P, Rutten-van M\u00f6lken M, Simpson J, Sin DD, Song Y, Suki B, Troosters T, Washko GR, Welte T, Dransfield MT (2022) Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 400(10356):921\u2013972","journal-title":"Lancet"},{"issue":"1","key":"844_CR9","doi-asserted-by":"publisher","first-page":"00036","DOI":"10.1183\/23120541.00036-2018","volume":"5","author":"HK Reddel","year":"2019","unstructured":"Reddel HK, Gerhardsson de Verdier M, Agust\u00ed A, Anderson G, Beasley R, Bel EH, Janson C, Make B, Martin RJ, Pavord I, Price D, Keen C, Gardev A, Rennard S, Sver\u00e9us A, Bansal AT, Brannman L, Karlsson N, Nuevo J, Nyberg F, Young SS, Vestbo J (2019) Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res 5(1):00036\u201302018","journal-title":"ERJ Open Res"},{"issue":"11","key":"844_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/resp.14325","volume":"27","author":"A Agust\u00ed","year":"2022","unstructured":"Agust\u00ed A, Rapsomaniki E, Beasley R, Hughes R, M\u00fcllerov\u00e1 H, Papi A, Pavord ID, van den Berge M, Faner R (2022) Treatable traits in the NOVELTY study. Respirology 27(11):929\u2013940","journal-title":"Respirology"},{"key":"844_CR11","doi-asserted-by":"crossref","unstructured":"Reddel HK, Vestbo J, Agust\u00ed A, Anderson GP, Bansal AT, Beasley R, Bel EH, Janson C, Make B, Pavord ID, Price D, Rapsomaniki E, Karlsson N, Finch DK, Nuevo J, de Giorgio-Miller A, Alacqua M, Hughes R, M\u00fcllerov\u00e1 H, Gerhardsson de Verdier M; NOVELTY study investigators (2021) Heterogeneity within and between physician-diagnosed asthma and\/or COPD: NOVELTY cohort. Eur Respir J 58(3):2003927","DOI":"10.1183\/13993003.03927-2020"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.2147\/COPD.S330817","volume":"16","author":"J Cardoso","year":"2021","unstructured":"Cardoso J, Ferreira AJ, Guimar\u00e3es M, Oliveira AS, Sim\u00e3o P, Sucena M (2021) Treatable traits in COPD - a proposed approach. Int J Chron Obstruct Pulmon Dis 16:3167\u20133182","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"844_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0118-2021","volume":"17","author":"K Duszyk","year":"2021","unstructured":"Duszyk K, McLoughlin RF, Gibson PG, McDonald VM (2021) The use of treatable traits to address COPD complexity and heterogeneity and to inform the care. Breathe (Sheff) 17(4):210118","journal-title":"Breathe (Sheff)"},{"issue":"1","key":"844_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01954-6","volume":"23","author":"A Marques","year":"2022","unstructured":"Marques A, Souto-Miranda S, Machado A, Oliveira A, J\u00e1come C, Cruz J, Enes V, Afreixo V, Martins V, Andrade L, Valente C, Ferreira D, Sim\u00e3o P, Brooks D, Tavares AH (2022) COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time. Respir Res 23(1):30","journal-title":"Respir Res"},{"issue":"2","key":"844_CR15","doi-asserted-by":"publisher","first-page":"00934","DOI":"10.1183\/23120541.00934-2020","volume":"7","author":"MR Sarwar","year":"2021","unstructured":"Sarwar MR, McDonald VM, Abramson MJ, Paul E, George J (2021) Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD. ERJ Open Res 7(2):00934\u201302020","journal-title":"ERJ Open Res"},{"issue":"3","key":"844_CR16","doi-asserted-by":"publisher","first-page":"2100627","DOI":"10.1183\/13993003.00627-2021","volume":"58","author":"R Louis","year":"2021","unstructured":"Louis R, Louis G, Bonhomme O (2021) Novelty: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice. Eur Respir J 58(3):2100627","journal-title":"Eur Respir J"},{"issue":"3","key":"844_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaip.2020.09.046","volume":"9","author":"SA Hiles","year":"2021","unstructured":"Hiles SA, Gibson PG, Agust\u00ed A, McDonald VM (2021) Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract 9(3):1255-1264.e2","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"844_CR18","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.jaip.2022.05.012","volume":"10","author":"MR Sarwar","year":"2022","unstructured":"Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J (2022) Effectiveness of interventions targeting treatable traits for the management of obstructive airway diseases: A systematic review and meta-analysis. J Allergy Clin Immunol Pract 10(9):2333-2345.e21","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"844_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1183\/09031936.06.00063205","volume":"28","author":"A Casas","year":"2006","unstructured":"Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hern\u00e1ndez C, Alonso A, del Pozo F, de Toledo P, Ant\u00f3 JM, Rodr\u00edguez-Rois\u00edn R, Decramer M (2006) Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 28(1):123\u2013130","journal-title":"Eur Respir J"},{"issue":"7","key":"844_CR20","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.rmed.2007.01.012","volume":"101","author":"J Garcia-Aymerich","year":"2007","unstructured":"Garcia-Aymerich J, Hernandez C, Alonso A, Casas A, Rodriguez-Roisin R, Anto JM, Roca J (2007) Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med 101(7):1462\u20131469","journal-title":"Respir Med"},{"issue":"7","key":"844_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/thoraxjnl-2012-202646","volume":"68","author":"VM McDonald","year":"2013","unstructured":"McDonald VM, Higgins I, Wood LG, Gibson PG (2013) Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 68(7):691\u2013694","journal-title":"Thorax"},{"key":"844_CR22","doi-asserted-by":"publisher","first-page":"15022","DOI":"10.1038\/npjpcrm.2015.22","volume":"25","author":"C Hern\u00e1ndez","year":"2015","unstructured":"Hern\u00e1ndez C, Alonso A, Garcia-Aymerich J, Serra I, Marti D, Rodriguez-Roisin R, Narsavage G, Carmen Gomez M, Roca J (2015) Effectiveness of community-based integrated care in frail COPD patients: a randomised controlled trial. NPJ Prim Care Respir Med 25:15022","journal-title":"NPJ Prim Care Respir Med"},{"issue":"2","key":"844_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/thoraxjnl-2016-208396","volume":"72","author":"FW Ko","year":"2017","unstructured":"Ko FW, Cheung NK, Rainer TH, Lum C, Wong I, Hui DS (2017) Comprehensive care programme for patients with chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 72(2):122\u2013128","journal-title":"Thorax"},{"issue":"1","key":"844_CR24","doi-asserted-by":"publisher","first-page":"1701567","DOI":"10.1183\/13993003.01567-2017","volume":"51","author":"L Rose","year":"2018","unstructured":"Rose L, Istanboulian L, Carriere L, Thomas A, Lee HB, Rezaie S, Shafai R, Fraser I (2018) Program of integrated care for patients with chronic obstructive pulmonary disease and multiple comorbidities (PIC COPD+): a randomised controlled trial. Eur Respir J 51(1):1701567","journal-title":"Eur Respir J"},{"key":"844_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107086","volume":"206","author":"S Souto-Miranda","year":"2023","unstructured":"Souto-Miranda S, Rocha V, Mendes MA, Sim\u00e3o P, Martins V, Spruit MA, Marques A (2023) The presence of extra-pulmonary treatable traits increases the likelihood of responding to pulmonary rehabilitation. Respir Med 206:107086","journal-title":"Respir Med"},{"issue":"12","key":"844_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/resp.14610","volume":"28","author":"M Thomas","year":"2023","unstructured":"Thomas M, Beasley R (2023) The treatable traits approach to adults with obstructive airways disease in primary and secondary care. Respirology 28(12):1101\u20131116","journal-title":"Respirology"},{"issue":"1","key":"844_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41533-024-00381-y","volume":"34","author":"A Agust\u00ed","year":"2024","unstructured":"Agust\u00ed A, Gibson PG, Heaney LG, Thomas M (2024) Change is in the air: key questions on the \u201cTreatable Traits\u201d model for chronic airway diseases in primary care. NPJ Prim Care Respir Med 34(1):21","journal-title":"NPJ Prim Care Respir Med"},{"issue":"8","key":"844_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/17512433.2021.1925537","volume":"14","author":"MG Matera","year":"2021","unstructured":"Matera MG, Calzetta L, Annibale R, Russo F, Cazzola M (2021) Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol 14(8):1015\u20131027","journal-title":"Expert Rev Clin Pharmacol"},{"key":"844_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/COPD.S419056","volume":"18","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Hanania NA, Page CP, Matera MG (2023) Novel anti-inflammatory approaches to COPD. Int J Chron Obstruct Pulmon Dis 18:1333\u20131352","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"844_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/164_2016_62","volume":"237","author":"PJ Barnes","year":"2017","unstructured":"Barnes PJ (2017) Glucocorticosteroids. Handb Exp Pharmacol 237:93\u2013115","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"844_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.amjmed.2021.09.006","volume":"135","author":"IM Adcock","year":"2022","unstructured":"Adcock IM, Bhatt SP, Balkissoon R, Wise RA (2022) The use of inhaled corticosteroids for patients with COPD who continue to smoke cigarettes: an evaluation of current practice. Am J Med 135(3):302\u2013312","journal-title":"Am J Med"},{"issue":"1","key":"844_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/pr.119.018150","volume":"72","author":"MG Matera","year":"2020","unstructured":"Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M (2020) Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev 72(1):218\u2013252","journal-title":"Pharmacol Rev"},{"key":"844_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coph.2020.11.003","volume":"56","author":"MG Matera","year":"2021","unstructured":"Matera MG, Cazzola M, Page C (2021) Prospects for COPD treatment. Curr Opin Pharmacol 56:74\u201384","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"844_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/17460441.2025.2490251","volume":"20","author":"L Calzetta","year":"2025","unstructured":"Calzetta L, Pistocchini E, Gholamalishahi S, Grugni L, Cazzola M, Rogliani P (2025) Novel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments. Expert Opin Drug Discov 20(5):683\u2013692","journal-title":"Expert Opin Drug Discov"},{"issue":"12","key":"844_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/17512433.2024.2438187","volume":"17","author":"M Cazzola","year":"2024","unstructured":"Cazzola M, Calzetta L, Rogliani P, Matera MG (2024) The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol 17(12):1149\u20131161","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"844_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","volume":"208","author":"A Anzueto","year":"2023","unstructured":"Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F (2023) Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: Randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med 208(4):406\u2013416","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"844_CR37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","volume":"191","author":"SI Rennard","year":"2015","unstructured":"Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H (2015) CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191(9):1001\u20131011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"844_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/17476348.2020.1732821","volume":"14","author":"C Pelaia","year":"2020","unstructured":"Pelaia C, Vatrella A, Sciacqua A, Terracciano R, Pelaia G (2020) Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Rev Respir Med 14(5):485\u2013491","journal-title":"Expert Rev Respir Med"},{"key":"844_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.intimp.2016.03.027","volume":"35","author":"V Gupta","year":"2016","unstructured":"Gupta V, Khan A, Higham A, Lemon J, Sriskantharajah S, Amour A, Hessel EM, Southworth T, Singh D (2016) The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils. Int Immunopharmacol 35:155\u20131627","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"844_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-025-02179-9","volume":"85","author":"M Cazzola","year":"2025","unstructured":"Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG (2025) PI3K inhibitors as potential therapeutic agents for the treatment of COPD with associated atherosclerosis. Drugs 85(6):741\u2013753","journal-title":"Drugs"},{"issue":"2","key":"844_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14712598.2022.2160238","volume":"23","author":"MG Matera","year":"2023","unstructured":"Matera MG, Calzetta L, Cazzola M, Ora J, Rogliani P (2023) Biologic therapies for chronic obstructive pulmonary disease. Expert Opin Biol Ther 23(2):163\u2013173","journal-title":"Expert Opin Biol Ther"},{"key":"844_CR42","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2147\/COPD.S428391","volume":"18","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Rogliani P, Blasi F (2023) Can treatable traits be the approach to addressing the complexity and heterogeneity of COPD? Int J Chron Obstruct Pulmon Dis 18:1959\u20131964","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"17","key":"844_CR43","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID (2025) Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med 392(17):1710\u20131720","journal-title":"N Engl J Med"},{"issue":"24","key":"844_CR44","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB (2024) Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 390(24):2274\u20132283","journal-title":"N Engl J Med"},{"key":"844_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-404717-4.00004-4","volume":"66","author":"SF Ziegler","year":"2013","unstructured":"Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H (2013) The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol 66:129\u2013155","journal-title":"Adv Pharmacol"},{"issue":"1","key":"844_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist \u00c5, Go\u0142\u0105bek M, Sindhwani NS, Ponnarambil SS (2025) Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med 13(1):47\u201358","journal-title":"Lancet Respir Med"},{"issue":"5","key":"844_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","volume":"10","author":"AJ Yousuf","year":"2022","unstructured":"Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, Haldar K, Wright A, Novotny P, Parker S, Glover S, Finch J, Quann N, Brookes CL, Hobson R, Ibrahim W, Russell RJ, John C, Grimbaldeston MA, Choy DF, Cheung D, Steiner M, Greening NJ, Brightling CE (2022) Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med 10(5):469\u2013477","journal-title":"Lancet Respir Med"},{"issue":"11","key":"844_CR48","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H (2021) Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 9(11):1288\u20131298","journal-title":"Lancet Respir Med"},{"key":"844_CR49","doi-asserted-by":"publisher","unstructured":"Singh D, Guller P, Reid F, Doffman S, Sepp\u00e4l\u00e4 U, Psallidas I, Moate R, Smith R, Kiraga J, Jimenez E, Brooks D, Kelly A, Nordenmark LH, Waqas Sadiq M, Mateos Caballero L, Kell C, Belvisi MG, Pandya H (2025) A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: frontier-4. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02231-2024","DOI":"10.1183\/13993003.02231-2024"},{"issue":"4","key":"844_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043786","volume":"24","author":"ME Christopoulou","year":"2023","unstructured":"Christopoulou ME, Papakonstantinou E, Stolz D (2023) Matrix metalloproteinases in chronic obstructive pulmonary disease. Int J Mol Sci 24(4):3786","journal-title":"Int J Mol Sci"},{"key":"844_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122874","volume":"352","author":"H Agraval","year":"2024","unstructured":"Agraval H, Kandhari K, Yadav UCS (2024) MMPs as potential molecular targets in epithelial-to-mesenchymal transition driven COPD progression. Life Sci 352:122874","journal-title":"Life Sci"},{"issue":"4","key":"844_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4168\/aair.2022.14.4.361","volume":"14","author":"J Ham","year":"2022","unstructured":"Ham J, Kim J, Ko YG, Kim HY (2022) The dynamic contribution of neutrophils in the chronic respiratory diseases. Allergy Asthma Immunol Res 14(4):361\u2013378","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"844_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.chest.2017.03.056","volume":"152","author":"E Polverino","year":"2017","unstructured":"Polverino E, Rosales-Mayor E, Dale GE, Dembowsky K, Torres A (2017) The role of neutrophil elastase inhibitors in lung diseases. Chest 152(2):249\u2013262","journal-title":"Chest"},{"issue":"7","key":"844_CR54","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543776.2019.1630379","volume":"29","author":"L Crocetti","year":"2019","unstructured":"Crocetti L, Quinn MT, Schepetkin IA, Giovannoni MP (2019) A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014\u20132018) and their therapeutic applications. Expert Opin Ther Pat 29(7):555\u2013578","journal-title":"Expert Opin Ther Pat"},{"key":"844_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pharmthera.2018.05.011","volume":"190","author":"B Korkmaz","year":"2018","unstructured":"Korkmaz B, Caughey GH, Chapple I, Gauthier F, Hirschfeld J, Jenne DE, Kettritz R, Lalmanach G, Lamort AS, Lauritzen C, \u0141\u0229gowska M, Lesner A, Marchand-Adam S, McKaig SJ, Moss C, Pedersen J, Roberts H, Schreiber A, Seren S, Thakker NS (2018) Therapeutic targeting of cathepsin C: from pathophysiology to treatment. Pharmacol Ther 190:202\u2013236","journal-title":"Pharmacol Ther"},{"issue":"16","key":"844_CR56","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML (2025) Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 392(16):1569\u20131581","journal-title":"N Engl J Med"},{"issue":"155","key":"844_CR57","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0073-2019","volume":"29","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Stolz D, Rogliani P, Matera MG (2020) \u03b11-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev 29(155):190073","journal-title":"Eur Respir Rev"},{"issue":"7","key":"844_CR58","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1164\/rccm.168.7.818","volume":"168","author":"American Thoracic Society; European Respiratory Society","year":"2003","unstructured":"American Thoracic Society; European Respiratory Society (2003) American thoracic society\/European respiratory society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168(7):818\u2013900","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"844_CR59","first-page":"412","volume":"44","author":"AD Wells","year":"2019","unstructured":"Wells AD, Woods A, Hilleman DE, Malesker MA (2019) Alpha-1 antitrypsin replacement in patients with COPD. P T 44(7):412\u2013415","journal-title":"P T"},{"key":"844_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113643","volume":"382","author":"X Liu","year":"2025","unstructured":"Liu X, Ucakar B, Vanvarenberg K, Marbaix E, Vanbever R (2025) Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy. J Control Release 382:113643","journal-title":"J Control Release"},{"key":"844_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.freeradbiomed.2020.11.030","volume":"163","author":"MJ McNulty","year":"2021","unstructured":"McNulty MJ, Silberstein DZ, Kuhn BT, Padgett HS, Nandi S, McDonald KA, Cross CE (2021) Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: updates, challenges and perspectives. Free Radic Biol Med 163:10\u201330","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"844_CR62","first-page":"282","volume":"11","author":"ML Brantly","year":"2024","unstructured":"Brantly ML, Kuhn BT, Farah HW, Mahadeva R, Cole A, Chang CL, Brown CD, Campos MA, Lascano JE, Babcock EK, Bhagwat SP, Boyea TF, Veldstra CA, Andrianov V, Kalabus JL, Eckelman BP, Veale AG (2024) Recombinant alpha-1 antitrypsin-Fc fusion protein INBRX-101 in adults with alpha-1 antitrypsin deficiency: a phase 1 study. Chronic Obstr Pulm Dis 11(3):282\u2013292","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"154","key":"844_CR63","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0095-2019","volume":"28","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Rogliani P, Matera MG (2019) The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev 28(154):190095","journal-title":"Eur Respir Rev"},{"issue":"2","key":"844_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.arbres.2021.06.005","volume":"58","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Rogliani P, Matera MG (2022) The future of bronchodilators in COPD and asthma. Arch Bronconeumol 58(2):107\u2013108","journal-title":"Arch Bronconeumol"},{"issue":"6","key":"844_CR65","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1021\/acsptsci.0c00127","volume":"3","author":"D Kim","year":"2020","unstructured":"Kim D, An SS, Lam H, Leahy JW, Liggett SB (2020) Identification and characterization of novel bronchodilator agonists acting at human airway smooth muscle cell TAS2R5. ACS Pharmacol Transl Sci 3(6):1069\u20131075","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"844_CR66","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaci.2020.04.036","volume":"146","author":"B Camoretti-Mercado","year":"2020","unstructured":"Camoretti-Mercado B, Lockey RF (2020) Bitter taste receptors in the treatment of asthma: opportunities and challenges. J Allergy Clin Immunol 146(4):776\u2013779","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"844_CR67","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.7150\/thno.92492","volume":"14","author":"K Ni","year":"2024","unstructured":"Ni K, Che B, Gu R, Wang C, Xu H, Li H, Cen S, Luo M, Deng L (2024) Bitterdb database analysis plus cell stiffness screening identify flufenamic acid as the most potent TAS2R14-based relaxant of airway smooth muscle cells for therapeutic bronchodilation. Theranostics 14(4):1744\u20131763","journal-title":"Theranostics"},{"key":"844_CR68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pupt.2018.04.004","volume":"50","author":"C Li","year":"2018","unstructured":"Li C, Liu PP, Tang DD, Song R, Zhang YQ, Lei S, Wu SJ (2018) Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension. Pulm Pharmacol Ther 50:111\u2013122","journal-title":"Pulm Pharmacol Ther"},{"key":"844_CR69","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.coph.2018.04.008","volume":"40","author":"RA Panettieri","year":"2018","unstructured":"Panettieri RA, Pera T, Liggett SB, Benovic JL, Penn RB (2018) Pepducins as a potential treatment strategy for asthma and COPD. Curr Opin Pharmacol 40:120\u2013125","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"844_CR70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1165\/rcmb.2019-0001OC","volume":"62","author":"CJ Koziol-White","year":"2020","unstructured":"Koziol-White CJ, Ghosh A, Sandner P, Erzurum SE, Stuehr DJ, Panettieri RA Jr (2020) Soluble guanylate cyclase agonists induce bronchodilation in human small airways. Am J Respir Cell Mol Biol 62(1):43\u201348","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"844_CR71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.23736\/S0026-4806.21.07283-9","volume":"113","author":"EB Gebski","year":"2022","unstructured":"Gebski EB, Anaspure O, Panettieri RA, Koziol-White CJ (2022) Airway smooth muscle and airway hyperresponsiveness in asthma: mechanisms of airway smooth muscle dysfunction. Minerva Med 113(1):4\u201316","journal-title":"Minerva Med"},{"key":"844_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111894","volume":"141","author":"H Guo","year":"2021","unstructured":"Guo H, Yang R, He J, Chen K, Yang W, Liu J, Xiao K, Li H (2021) Edaravone combined with dexamethasone exhibits synergic effects on attenuating smoke-induced inhalation lung injury in rats. Biomed Pharmacother 141:111894","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"844_CR73","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.burns.2022.03.010","volume":"48","author":"P Cui","year":"2022","unstructured":"Cui P, Tang Z, Zhan Q, Deng C, Lai Y, Zhu F, Xin H, Li R, Chen A, Tong Y (2022) In vitro and vivo study of tranilast protects from acute respiratory distress syndrome and early pulmonary fibrosis induced by smoke inhalation. Burns 48(4):880\u2013895","journal-title":"Burns"},{"issue":"34","key":"844_CR74","doi-asserted-by":"publisher","first-page":"38421","DOI":"10.1021\/acsami.2c05220","volume":"14","author":"S He","year":"2022","unstructured":"He S, Wu L, Sun H, Wu D, Wang C, Ren X, Shao Q, York P, Tong J, Zhu J, Li Z, Zhang J (2022) Antioxidant biodegradable covalent cyclodextrin frameworks as particulate carriers for inhalation therapy against acute lung injury. ACS Appl Mater Interfaces 14(34):38421\u201338435","journal-title":"ACS Appl Mater Interfaces"},{"issue":"734","key":"844_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi3360","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Meng Z, Liu M, Zhou Y, Chen D, Zhao Y, Zhang T, Zhong N, Dai X, Li S, Zuo W (2024) Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy. Sci Transl Med 16(734):eadi3360","journal-title":"Sci Transl Med"},{"issue":"16","key":"844_CR76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2400077121","volume":"121","author":"S Shao","year":"2024","unstructured":"Shao S, Zhang N, Specht GP, You S, Song L, Fu Q, Huang D, You H, Shu J, Domissy A, Li S, Nguyen-Tran V, Joseph SB, Chatterjee AK, Chen JJ, Schultz PG, Bollong MJ (2024) Pharmacological expansion of type 2 alveolar epithelial cells promotes regenerative lower airway repair. Proc Natl Acad Sci U S A 121(16):e2400077121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"844_CR77","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1126\/sciadv.abj9949","volume":"8","author":"X Wu","year":"2022","unstructured":"Wu X, Bos IST, Conlon TM, Ansari M, Verschut V, van der Koog L, Verkleij LA, D\u2019Ambrosi A, Matveyenko A, Schiller HB, K\u00f6nigshoff M, Schmidt M, Kistemaker LEM, Yildirim A\u00d6, Gosens R (2022) A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration. Sci Adv 8(12):9949","journal-title":"Sci Adv"},{"issue":"1","key":"844_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/pharmaceutics15010037","volume":"15","author":"T Akita","year":"2022","unstructured":"Akita T, Morita Y, Kawai T, Oda K, Tange K, Nakai Y, Yamashita C (2022) Am 80-encapsulated lipid nanoparticles, developed with the aim of achieving alveolar regeneration, have an improvement effect on pulmonary emphysema. Pharmaceutics 15(1):37","journal-title":"Pharmaceutics"},{"issue":"4","key":"844_CR79","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1164\/rccm.202303-0400SO","volume":"208","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Rogliani P, Barnes PJ, Blasi F, Celli B, Hanania NA, Martinez FJ, Miller BE, Miravitlles M, Page CP, Tal-Singer R, Matera MG (2023) An update on outcomes for COPD pharmacological trials: a COPD investigators report - reassessment of the 2008 American Thoracic Society\/European Respiratory Society statement on outcomes for COPD pharmacological trials. Am J Respir Crit Care Med 208(4):374\u2013394","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"844_CR80","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","volume":"17","author":"DC Angus","year":"2020","unstructured":"Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, Cheng AC, Chiche JD, De Jong M, Detry M, Goossens H, Gordon A, Green C, Higgins AM, Hullegie SJ, Kruger P, Lamontagne F, Litton E, Marshall J, McGlothlin A, McGuinness S, Mouncey P, Murthy S, Nichol A, O\u2019Neill GK, Parke R, Parker J, Rohde G, Rowan K, Turner A, Young P, Derde L, McArthur C, Webb SA (2020) The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) study. Rationale and design. Ann Am Thorac Soc 17(7):879\u2013891","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"844_CR81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Yee D (2019) I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 11(4):303\u2013310","journal-title":"Curr Breast Cancer Rep"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-025-00844-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-025-00844-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-025-00844-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:02:09Z","timestamp":1766379729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-025-00844-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s00408-025-00844-0","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"92"}}